Promising Blood-Based Biomarkers for Melanoma: Recent Progress of Liquid Biopsy and Its Future Perspectives

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Current Treatment Options in Oncology

• Publication date

  2022-03-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11864-022-00948-2PMID 35298769
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma

  2021cited by this paper
• NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-Cancer Cell-Free Assay

  2021cited by this paper
• Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients.

  2021cited by this paper
• The predictive and prognostic significance of cell‐free DNA concentration in melanoma

  2020cited by this paper
• Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma

  2020cited by this paper
• The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients

  2020cited by this paper
• Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells

  2020cited by this paper
• Circulating Tumor Cells and Early Relapse in Node-positive Melanoma

  2020cited by this paper
• Significance of 5-S-Cysteinyldopa as a Marker for Melanoma

  2020cited by this paper
• A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients

  2020cited by this paper
• Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients

  2020cited by this paper
• Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management

  2020cited by this paper
• MiR-424 Functions as Potential Diagnostic and Prognostic Biomarker in Melanoma.

  2020cited by this paper
• Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA

  2020cited by this paper
• Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis

  2020cited by this paper
• Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients.

  2020cited by this paper
• MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma.

  2019cited by this paper
• Circulating microRNAs as biomarkers for early diagnosis of cutaneous melanoma

  2019cited by this paper
• A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision

  2019cited by this paper
• Detection and Characterization of Circulating Tumor Cells by Quantitative Real-Time PCR.

  2019cited by this paper
• Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

  2019cited by this paper
• Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing

  2019cited by this paper
• Circulating MicroRNAs in Cancer: Potential and Challenge

  2019cited by this paper
• Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

  2019cited by this paper
• MicroRNA‐203 reinforces stemness properties in melanoma and augments tumorigenesis in vivo

  2019cited by this paper
• ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab

  2019cited by this paper
• Multiplex Gene Profiling of Cell-Free DNA in Patients With Metastatic Melanoma for Monitoring Disease.

  2018cited by this paper
• Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients

  2018cited by this paper
• Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy

  2018cited by this paper
• Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy

  2018cited by this paper
• Serum exosomal microRNAs as potent circulating biomarkers for melanoma

  2018cited by this paper
• Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy

  2018cited by this paper
• Development and validation of a plasma-based melanoma biomarker suitable for clinical use

  2018cited by this paper
• Diversity of circulating tumor cells in peripheral blood: Detection of heterogeneous BRAF mutations in a patient with advanced melanoma by single-cell analysis.

  2018cited by this paper
• Abstract LB-144: Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy

  2018cited by this paper
• Feasibility of monitoring advanced melanoma patients using cell‐free DNA from plasma

  2018cited by this paper
• The Circulating Transcriptome as a Source of Biomarkers for Melanoma

  2018cited by this paper
• Upregulation of Serum miR-10b Is Associated with Poor Prognosis in Patients with Melanoma

  2017cited by this paper
• Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

  2017cited by this paper
• Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.

  2017cited by this paper
• Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device

  2017cited by this paper
• Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma

  2017cited by this paper
• Overcoming resistance to BRAF inhibitors.

  2017cited by this paper
• Down-regulated miR-23a Contributes to the Metastasis of Cutaneous Melanoma by Promoting Autophagy

  2017cited by this paper
• Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients

  2016cited by this paper
• Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

  2016cited by this paper
• Quantitative analysis of the BRAFV600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR

  2016cited by this paper
• Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.

  2016cited by this paper
• Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

  2016cited by this paper
• Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline

  2016cited by this paper
• Sensitivity of plasma BRAFmutant and NRASmutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression

  2016cited by this paper
• Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer

  2016cited by this paper
• BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors

  2015cited by this paper
• Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations

  2015cited by this paper
• Serum‐based miRNAs in the prediction and detection of recurrence in melanoma patients

  2015cited by this paper
• Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment

  2015cited by this paper
• MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis

  2015cited by this paper
• miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic implications

  2015cited by this paper
• The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis☆

  2015cited by this paper
• Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

  2015cited by this paper
• A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients

  2015cited by this paper
• Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

  2015cited by this paper
• Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma.

  2015cited by this paper
• High-Density Dielectrophoretic Microwell Array for Detection, Capture, and Single-Cell Analysis of Rare Tumor Cells in Peripheral Blood

  2015cited by this paper
• Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.

  2015cited by this paper
• Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer?

  2015cited by this paper
• Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma

  2014cited by this paper
• Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma

  2014cited by this paper
• Quantitative Cell-Free Circulating BRAF Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors

  2014cited by this paper
• Circulating miR-221 Expression Level and Prognosis of Cutaneous Malignant Melanoma

  2014cited by this paper
• Epigenetic biomarkers in skin cancer.

  2014cited by this paper
• Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade

  2014cited by this paper
• Analysis of circulating tumor DNA to monitor metastatic breast cancer.

  2013cited by this paper
• A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study

  2013cited by this paper
• Sensitive detection of melanoma metastasis using circulating microRNA expression profiles

  2013cited by this paper
• Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics.

  2013cited by this paper
• Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.

  2013cited by this paper
• Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

  2013cited by this paper
• Liquid biopsy: monitoring cancer-genetics in the blood

  2013cited by this paper
• Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.

  2013cited by this paper
• An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

  2013cited by this paper
• Plasma microRNA-21 is associated with tumor burden in cutaneous melanoma.

  2013cited by this paper
• Serum microRNAs as biomarkers for recurrence in melanoma

  2012cited by this paper
• The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker.

  2011cited by this paper
• High-throughput miRNA profiling of human melanoma blood samples

  2010cited by this paper
• Old and new serological biomarkers in melanoma: where we are in 2009

  2010cited by this paper
• Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma

  2010cited by this paper
• Circulating mutant DNA to assess tumor dynamics

  2008cited by this paper
• Circulating microRNAs as stable blood-based markers for cancer detection

  2008cited by this paper
• Cancer biomarkers: current issues and future directions.

  2007cited by this paper
• Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers.

  2007cited by this paper
• Oncomirs — microRNAs with a role in cancer

  2006cited by this paper
• Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma.

  2006cited by this paper
• MicroRNA signatures in human cancers

  2006cited by this paper
• Estrogen receptor-alpha methylation predicts melanoma progression.

  2006cited by this paper
• Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.

  2005cited by this paper
• Highly Sensitive Detection of Melanoma at an Early Stage Based on the Increased Serum Secreted Protein Acidic and Rich in Cysteine and Glypican-3 Levels

  2005cited by this paper
• Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma.

  2003cited by this paper
• A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma.

  2001cited by this paper
• Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence.

  2000cited by this paper

• Integrating cuproptosis- and ferroptosis-related gene signatures to predict prognosis, immunotherapy response, and drug sensitivity in patients with skin cutaneous melanoma

  2026cites this paper
• Predictive Factors for Sentinel Lymph Node Positivity in Melanoma Patients—The Role of Liquid Biopsy, MicroRNA and Gene Expression Profile Panels

  2025cites this paper
• Determining a Stability Prognostic Panel for 636 Patients With Melanoma Using a Machine Learning Computational Framework

  2025cites this paper
• Design, Development, and Clinical Validation of a Novel Kit for Cell-Free DNA Extraction

  2025cites this paper
• Extracellular vesicle-derived non-coding RNAs in remodeling melanoma.

  2024cites this paper
• Melanoma’s New Frontier: Exploring the Latest Advances in Blood-Based Biomarkers for Melanoma

  2024cites this paper
• Human CD79b+ neutrophils in the blood are associated with early-stage melanoma

  2023cites this paper
• Increased circulating exosomal Janus kinase 2 messenger RNA levels in psoriasis

  2023cites this paper
• Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting

  2023cites this paper
• Elevated expression of miR-301a and its functional roles in canine oral melanoma.

  2023cites this paper
• Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction

  2022cites this paper
• Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples

  2022cites this paper